Personalized medicine and atrial fibrillation: will it ever happen?

Steven A Lubitz* and Patrick T Ellinor

Abstract:
Atrial fibrillation (AF) is a common arrhythmia of substantial public health importance. Recent evidence demonstrates a heritable component underlying AF, and genetic discoveries have identified common variants associated with the arrhythmia. Ultimately one hopes that the consideration of genetic variation in clinical practice may enhance care and improve health outcomes. In this review we explore areas of potential clinical utility in AF management including those relating to pharmacogenetics and risk prediction.

Keywords: Atrial fibrillation, genetics, personalized medicine, risk prediction, pharmacogenetics

Introduction:
Atrial fibrillation (AF) is a common cardiac arrhythmia marked by loss of coordinated atrial electrical and mechanical function. Among the potential consequences of AF are symptoms and decreased functional status [1], as well as increased risks of thromboembolic stroke, heart failure, and mortality [2]. Thus far, efforts to prevent AF have generally been limited, and therefore management is directed at preventing or alleviating adverse consequences of the arrhythmia.

In recent years, heritability underlying AF has been recognized [3-7]. AF risk is increased by about 40% if a first-degree relative has AF, and two-fold if that relative develops AF by age 65 [7]. Numerous genetic variants associated with AF have been reported through traditional mapping techniques such as linkage and candidate gene analyses [8]. For example, novel gain-of-function mutations in \( KCNE1 \) were recently described in this journal using a candidate gene approach in patients with early onset AF [9]. \( KCNE1 \) encodes the beta subunit of the potassium channel comprising the \( I_{KS} \) current, which governs atrial repolarization. Such gain-of-function mutations, and their expected shortening of the action potential duration, are consistent with electrical reentry as a predominant pathophysiological mechanism underlying AF [10]. Mutations in sodium, potassium, and calcium channel subunits, as well as in gap junction and non-ion channel proteins have been reported and are reviewed elsewhere (Table 1) [8,11].

Large-scale genome-wide association studies have identified nine common AF susceptibility loci (Table 1) [12-16]. In aggregate, these discoveries implicate cardiac ion channels, transcription factors central to cardiopulmonary development, and signaling molecules as common pathways involved in the development of AF. Prior to these genetic discoveries, the relations between many of these pathways and AF pathogenesis were unrecognized.

Genetic associations with AF have spawned an exciting new era of biological investigation. Integrating recent discoveries with previous insights about atrial remodeling and AF pathophysiology has led to resurgence of interest in exploiting biological pathways with pharmaceuticals for AF management [17,18]. Given the strong heritable component underlying AF, these discoveries also have elicited hope that determining genetic variation in patients will help individualize clinical management and improve health outcomes. The concept of applying knowledge of an individual’s genotype to clinical management is commonly referred to as personalized or precision medicine.

In many ways, as with most areas of clinical medicine, the management of patients with AF is already personalized [19,20]. Prescription of thromboembolism prophylaxis regimens is tailored for each patient. Bedside stroke and bleeding risk prediction rules [21-24] are available to help clinicians decide whether to prescribe aspirin or systemic anticoagulants. Cardioversions, antiarrhythmic therapy, and ablation for AF are variably prescribed depending on patient symptoms. When choosing which systemic anticoagulants or antiarrhythmic medications to...
prescribe, clinicians consider comorbidities, drug efficacy, adverse effects, contraindications, pharmacologic interactions, and cost. Ablation procedures for patients with persistent AF are more extensive than for those with paroxysmal AF [25].

Despite the personalized nature of AF management, care of patients with AF is challenging owing to the complexity of the arrhythmia. Patient management is limited by unpredictable recurrence and progression of AF, differing susceptibilities to stroke and heart failure, and variable treatment responses. These challenges are opportunities for diagnostic and therapeutic innovation, and represent areas where genetic medicine might facilitate clinical management. Two promising areas for the near-term application of genetic information in AF include pharmacological management and risk prediction (Table 2).

### Potential areas for clinical application of genetic information

#### Pharmacogenetics

Many medications used for AF treatment have narrow therapeutic margins. Antiarrhythmic efficacy is only about 50% at 12 months [26], and prohibitive adverse effects such as proarrhythmia or other reactions may occur [27,28]. Thromboembolism prophylaxis with warfarin is limited by increased risks of disabling stroke among subtherapeutic patients, and bleeding among those with supratherapeutic doses [29].

Can the effectiveness and safety of pharmacologic agents used in AF be improved by utilizing genetic information? Pharmacogenetics refers to how genetic variation accounts for differences in drug responses among individuals. Measurable differences in pharmacodynamics (that is, the interaction of drugs with their target molecules) and pharmacokinetics (that is, properties relating to drug uptake, distribution, duration of effect, metabolism, excretion, and so on) are likely to be associated with genetic variation. In a recent proof-of-concept paper, whole genome sequencing in a single individual identified over 60 previously reported pharmacogenetic variants affecting drug response [30].

A high-profile example of a pharmacogenetic effect relevant to AF management relates to warfarin. Warfarin dose requirements have been linked to variation in

| Gene       | Mechanism                                      | Ref.   | Chromosomal locus | Candidate gene | Ref.   |
|------------|------------------------------------------------|--------|-------------------|----------------|--------|
| KCNQ1      | Enhanced repolarization (increased \( \dot{I}_K \)) | [61-65] | 1q21              | IL6R           | [66]   |
| KCNE1      | Enhanced repolarization (increased \( \dot{I}_K \)) | [9,67-69] | 1q21              | KCNN3          | [15,16]|
| KCNE2      | Enhanced repolarization (increased \( \dot{I}_K \)) | [70]   | 1q24              | PRKX1          | [16]   |
| KCNES      | Enhanced repolarization (increased \( \dot{I}_K \)) | [71]   | 4q25              | PITX2          | [12-16]|
| KCNH2      | Enhanced repolarization (increased \( \dot{I}_K \)) | [72,73] | 7q31              | CAV1           | [16]   |
| KCNQ2      | Enhanced repolarization (increased \( \dot{I}_K \)) | [74]   | 9q22              | CdeG3          | [16]   |
| KCNQ5      | Delayed repolarization and afterdepolarizations (decreased \( \dot{I}_{Na} \)) | [75]   | 10q22             | SYNP2L/MY0Z1   | [16]   |
| Sodium channel |                       |        |                   |                |        |
| SCN5A      | Hyperpolarizing shift in inactivation (loss-of-function)/depolarizing shift in inactivation (gain-of-function) | [76-81] | 15q24             | HCN4          | [16]   |
| SCN1B      | Decreased \( \dot{I}_{Na} \) current and altered channel gating | [82]   | 16q22             | ZFH3X          | [16]   |
| SCN2B      | Decreased \( \dot{I}_{Na} \) current and altered channel gating | [82]   | Familial loci with unknown gene | 6q14-q16 | - | [83]   |
| Ion channel-related |                       |        |                   |                |        |
| GNAS      | Impaired cellular transport and intercellular electrical coupling, increased dispersion of refractoriness | [84-87] | 10p11-q21         | -             | [88]   |
| ANK2       | Loss-of-function reduces expression and membrane targeting of Ca\(_{\alpha,1.3}\) (decreased \( \dot{I}_{Ca,L} \)) | [89,90] | 10q22-q24         | -             | [91]   |
| Non-ion channel |                       |        |                   |                |        |
| LMNA       | Disruption of nuclear function or altered interaction with cytoplasmic proteins | [92-95] |                   |                |        |
| NUP155     | Reduced nuclear membrane permeability, enhanced repolarization | [96,97] |                   |                |        |
| AGT        | Unknown            | [98,99] |                   |                |        |
| ACE        | Insertion/deletion, unknown mechanism            | [100-102] |                   |                |        |
| NNPA       | Mutant peptide, enhanced repolarization         | [103]   |                   |                |        |

AF susceptibility genes were based on prior linkage mapping or candidate gene sequencing efforts. AF susceptibility loci were based on candidate gene chip or genome-wide association studies.
genes encoding products involved in warfarin pharmacokinetics and pharmacodynamics, respectively. Dosing algorithms that include genetic variation in these genes explain a striking one-third to one-half of the variability in warfarin dose requirements [33]. Accounting for variants in these genes may be particularly beneficial (1) during initiation of warfarin therapy when complications relating to excessive or underdosing are particularly prevalent, and (2) for identifying individuals with unexpectedly high or low therapeutic dose requirements [34] who may therefore be at elevated risk for thromboembolism or bleeding, respectively. The US Food and Drug Administration has advised physicians that genetic testing may improve initial dosing estimates among patients taking warfarin [35] and dosing prediction algorithms are available.

Nevertheless, routine warfarin testing has not been widely adopted for several reasons. Novel anticoagulants [36] and procedures [37] are emerging as potential alternatives to warfarin, rigorous surveillance may improve time spent in the therapeutic range thereby improving safety and efficacy [38], and logistical considerations such as costs and genetic literacy pose challenges to the adoption of genetic testing. Currently, the safety and efficacy of genotype-guided warfarin dosing is being compared to routine dosing in the ongoing Clarification of Optimal Warfarin Dosing through Genetics (COAG) trial (clinicaltrials.gov identifier NCT00839657).

Regardless of the outcome of this trial, the striking associations between genetic variants and warfarin doses have revealed the clinical potential for pharmacogenetics. Emerging reports demonstrate other associations between genetic variants and drug response. Genetic variation has been reported to associate with response to β-adrenergic antagonism in patients with AF [39], and genetic variation associates with drug-induced torsade de pointes [40,41]. Given the heterogeneity in the molecular mechanisms underlying AF [42], as well as variability in medication efficacy and adverse effects, there may be a practical role for pharmacogenetics in the management of patients with this arrhythmia. It is worth noting that genetic variation has also been reported to associate with AF recurrence after catheter ablation [43]; however, the role of genetic testing for a procedure in which success is dependent on many technical factors remains undefined.

The next steps for assessing the clinical utility of pharmacogenetics will involve performing systematic phenotyping, genotyping, and association testing of established and novel pharmacological agents used for AF management. Candidate genes that ought to be prioritized for screening include those encoding products involved in drug uptake or metabolism, and those encoding drug targets.

### Table 2 Potential areas for clinical application of genetic discoveries in atrial fibrillation (AF) management

| Area             | Example                             | Potential utility                                           | Limitations                                      |
|------------------|-------------------------------------|------------------------------------------------------------|--------------------------------------------------|
| Risk prediction  | Predict new-onset AF or AF-related morbidity (stroke, heart failure, mortality risk) | Benchmark for clinical trial development                  | Absence of known preventive strategies for AF    |
|                  |                                     | Facilitate AF and clinical outcome prevention              | Cohorts for genetic risk score derivation        |
|                  |                                     |                                                            | predominantly of European ancestry               |
|                  |                                     |                                                            | Small relative risks of discovered variants     |
|                  |                                     |                                                            | Complexity of incorporation into clinical practice |
|                  |                                     |                                                            | Cost                                             |
|                  |                                     |                                                            | Untested                                         |
|                  | Predict AF progression               | Early antiarrhythmic or ablation intervention              | Clear relations between AF progression and morbidity and mortality |
| Patient          | Pharmacogenetics                     |                                                            | Un-tested                                       |
| management       |                                     |                                                            | Development of novel agents with wide therapeutic margins |
|                  |                                     |                                                            | Ablation and mechanical interventions as         |
|                  |                                     |                                                            | alternatives                                      |
|                  |                                     |                                                            | Complexity of incorporation into clinical practice |
|                  |                                     |                                                            | Cost                                             |
|                  |                                     |                                                            | Untested                                         |

CYP2C9 [31] and VKORC1 [32], genes encoding products involved in warfarin pharmacokinetics and pharmacodynamics, respectively. Dosing algorithms that include genetic variation in these genes explain a striking one-third to one-half of the variability in warfarin dose requirements [33]. Accounting for variants in these genes may be particularly beneficial (1) during initiation of warfarin therapy when complications relating to excessive or underdosing are particularly prevalent, and (2) for identifying individuals with unexpectedly high or low therapeutic dose requirements [34] who may therefore be at elevated risk for thromboembolism or bleeding, respectively. The US Food and Drug Administration has advised physicians that genetic testing may improve initial dosing estimates among patients taking warfarin [35] and dosing prediction algorithms are available.

Nevertheless, routine warfarin testing has not been widely adopted for several reasons. Novel anticoagulants [36] and procedures [37] are emerging as potential alternatives to warfarin, rigorous surveillance may improve time spent in the therapeutic range thereby improving safety and efficacy [38], and logistical considerations such as costs and genetic literacy pose challenges to the adoption of genetic testing. Currently, the safety and efficacy of genotype-guided warfarin dosing is being compared to routine dosing in the ongoing Clarification of Optimal Warfarin Dosing through Genetics (COAG) trial (clinicaltrials.gov identifier NCT00839657).

Regardless of the outcome of this trial, the striking associations between genetic variants and warfarin doses have revealed the clinical potential for pharmacogenetics. Emerging reports demonstrate other associations between genetic variants and drug response. Genetic variation has been reported to associate with response to β-adrenergic antagonism in patients with AF [39], and genetic variation associates with drug-induced torsade de pointes [40,41]. Given the heterogeneity in the molecular mechanisms underlying AF [42], as well as variability in medication efficacy and adverse effects, there may be a practical role for pharmacogenetics in the management of patients with this arrhythmia. It is worth noting that genetic variation has also been reported to associate with AF recurrence after catheter ablation [43]; however, the role of genetic testing for a procedure in which success is dependent on many technical factors remains undefined.

The next steps for assessing the clinical utility of pharmacogenetics will involve performing systematic phenotyping, genotyping, and association testing of established and novel pharmacological agents used for AF management. Candidate genes that ought to be prioritized for screening include those encoding products involved in drug uptake or metabolism, and those encoding drug targets.

### Risk prediction

Risk prediction encompasses estimation of AF probability and prediction of AF-related complications such as stroke, heart failure, and death. The goal of prediction algorithms is to identify individuals prior to the onset of AF or AF-related morbidity, and thereby help target prevention efforts. Estimation of risk may also assist with clinical trial development by enabling enrollment of individuals in a particular risk stratum.
Clinical prediction algorithms for new-onset AF have been developed in community-based cohorts of European and African American ancestry [44-46]. These algorithms have good but not excellent discriminative properties. In a given sample of individuals without AF, they correctly assigned a higher predicted risk to those who ultimately developed AF only about 60% to 70% of the time [44-46]. Simply flipping a coin would correctly assign a higher risk to those developing AF 50% of the time.

Can genetic discoveries improve risk prediction?
We and other investigators from the Framingham Heart Study tested whether accounting for the occurrence of AF in a first-degree relative (familial AF) improved AF risk prediction beyond clinical risk factors [7]. AF prediction improved slightly after accounting for familial AF. In a separate study from Sweden, adding genotypes for two common polymorphisms at the chromosome 4q25 and 16q22 AF susceptibility loci to clinical risk factors did not significantly improve AF risk prediction [47].

For most complex conditions, genetic risk scores have not achieved substantial improvements in discrimination over scores comprised of clinical risk factors. Yet enhancements in the understanding of genetic risk modeling reveal insights that may improve the utility of genetic risk scores in the future. For example, variants included in genetic risk scores to date have small effect sizes (for example, relative risks of 1.1 to 1.5). Single risk factors with such modest relative risks are unlikely to have meaningful impacts on discrimination alone [48]. Large-effect variants, which have greater potential to improve discrimination, are rare and not captured by genotyping panels used in genome-wide association studies.

Fine mapping and sequencing offer promise for the discovery of such large-effect variants [49]. For example in a fine mapping analysis we previously identified independent genetic variants at the chromosome 4q25 locus associated with AF [50]. A multimarker risk score comprised of genotypes tagging these three independent signals demonstrated that AF risk increased with an increasing number of AF risk alleles. The multimarker score identified about 12% of individuals with a twofold or greater relative risk for AF, and 1% with an estimated sixfold elevated risk of AF compared to those with the most common genotypes. This is one of the largest relative risks to date for a qualitative trait in the era of genome-wide association studies.

Another potential reason that genetic risk scores have not substantially improved prediction models is that few variants were tested. Accounting for additional genetic variants associated with conditions at far less stringent significance thresholds can substantially increase the proportion of variance explained by genetic factors [51-53]. In simulations, genetic profiling using large numbers of genetic variants significantly improved risk discrimination [54].

Novel metrics have been developed to assess clinical utility of prediction models, with increased recognition that measures of discrimination alone can be insensitive [55]. The role of novel prediction metrics with respect to genetic profiling has not been extensively explored.

Furthermore, although a widespread heritable component underlies AF, the arrhythmia may result from a variety of different pathological processes. Whether genetic profiling will successfully predict incident AF may depend on the extent to which the ‘type’ of AF studied is influenced by genetic factors. The importance of refining AF classification has been highlighted elsewhere [56,57], and may overcome the potential challenges that phenotypic heterogeneity presents to risk prediction efforts.

The absence of data demonstrating clinical utility of routinely using genotype information to guide clinical management in AF should not deter hope at this stage, but rather should be viewed as an opportunity for systematic testing of the clinical role of genetic information. Nevertheless, there is a risk that hype can obscure the monumental insights gained from the current era of genetic discovery. As an example, companies such as deCODE and 23andMe are performing direct to consumer genetic testing, and purport to calculate one’s genetic risk of AF based on one or a few polymorphisms associated with modestly increased relative risks of AF. These calculations are not based on well-defined genetic effect estimates, and do not consider other genetic risk factors, interactions between genes, the predictive utility of genetic risk markers, or competing risks. Moreover, in the absence of data regarding clinical risk factors and environmental exposures, how are these results to be interpreted? Problems with direct to consumer genetic testing are reinforced by recent literature highlighting the facts that patients often have misperceptions about the results genetic testing [58], and practitioners frequently lack confidence in explaining direct to consumer genetic testing results [59].

Summary
Owing to the absence of currently available outcome data, there is insufficient evidence to recommend routine testing for genetic variation in the management of patients with AF, as was highlighted by a recent Heart Rhythm Society and European Heart Rhythm Association consensus statement on genetic testing [60]. However, increased attention to pharmacogenetics and prediction modeling using genetic information offers
hope for improved clinical care. The absence of data demonstrating direct utility of incorporating genotype information into clinical practice provides an opportunity to systematically assess whether applying genetic data to clinical practice will enhance outcomes.

As with any new technology or development, systematic assessment of its utility in clinical medicine is warranted. Such assessment includes identifying suboptimal realms of clinical care, determining whether such areas present opportunities for application of genetic knowledge, testing whether genetic discoveries are superior to standard care for improving health outcomes, and evaluating whether the expected benefits of implementing genetic testing justify the resource utilization that would be necessary for its adoption.

Recent AF genetic discoveries herald a sea change in the approach to AF research. Investigation of the pathogenic mechanisms underlying this common and morbid arrhythmia is now informed by unbiased techniques, allowing investigators to branch out from preconceived biological mechanisms and reliance on established animal models of AF. It will take many years to realize the full impact of recent genetic discoveries. In the meantime, questions surrounding the utility of applying genetic discoveries to patient management will only be clarified by rigorous testing of genetic information in clinical practice. Ultimately, it is the opportunity for innovation, discovery, and improvement in health outcomes that makes this era of genetic discovery so exciting.

Authors’ contributions
SAL and PTE were involved in drafting the manuscript and revising it critically for important intellectual content. Both gave final approval of the manuscript.

Authors’ information
Steven Lubitz, MD, MPH is a cardiac electrophysiologist at the Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School. Patrick Ellinor, MD, PhD is a cardiac electrophysiologist at Massachusetts General Hospital and Associate Professor at Harvard Medical School.

Competing interests
The authors declare that they have no competing interests.

Acknowledgements
PTE is supported by NIH grants 1R01HL092577, 1R01HL104156, SRT120X027021 and 1K08HL105780. SAL is supported by an AHA grant 12FTF11350014 and a Corrigan Minehan Innovation in Cardiovascular Research Spark Award.

Received: 24 July 2012 Accepted: 4 December 2012 Published: 4 December 2012

References
1. Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF, Van Gelder IC, Ellinor PT, Benjamin EJ. Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. Circulation 2012, 125:2933-2943.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 2012, 125:e220.
3. Fox CS, Parise H, D’Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ, Levy D, Wolf PA, Benjamin EJ. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004, 291:2851-2855.
4. Ellinor PT, Yorger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. Hum Genet 2005, 116:179-184.
5. Amor DO, Thorvaldsson S, Manolio TA, Thorleifsson G, Kristjansson K, Hakonarson H, Stefansson K. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006, 27:708-712.
6. Christophersen IE, Ravn LS, Budtz-Joergensen E, Skytte A, Haunsoe S, Svendsen JH, Christensen K. Familial aggregation of atrial fibrillation: a study in Danish twins. Circ Arrhythm Electrophysiol 2009, 2:378-383.
7. Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Piao M, Villalon ML, Vasan RS, Pencina MJ, Levy D, Larson MG, Ellinor PT, Benjamin EJ. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA 2010, 304:2263-2269.
8. Mahida S, Lubitz SA, Rienstra M, Milan DJ, Ellinor PT. Monogenic atrial fibrillation as pathophysiological paradigms. Cardiovasc Res 2011, 89:692-700.
9. Olesen MS, Bentzen BH, Nielsen JB, Steffensen AB, David JP, Jabbari J, Jensen HK, Haunsoe S, Svendsen JH, Schmitt N. Mutations in the potassium channel subunit KCNE1 are associated with early-onset familial atrial fibrillation. BMC Med Genet 2012, 13:24.
10. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002, 415:219-226.
11. Shan J, Xie W, Betzenhauser M, Reiken S, Chen BX, Winsonka A, Marks AR. Calcium leak throughryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2012, 111:706-717.
12. Gudbjartsson DT, Amor DO, Helgadottir A, Gretarsdottr S, Holm H, Sigurjonsdottir A, Jonassott A, Baker A, Thorleifsson G, Kristjansson K, Palsson A, Blondal T, Sulem P, Backman VM, Hardarson GA, Palodottir E, Helgason A, Sigurjonsdottir B, Svavarsson J, Kautsli K, Ng MC, Baum L, So WY, Wong KS, Chan JC, Fute KL, Greenberg SM, Sale M, Kelly P, MacRae CA, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007, 448:353-357.
13. Benjamin EJ, Rice KM, Arking DE, Pfeiffer A, van Noord C, Smith AV, Schnabel RB, Bis JC, Boerwinkle E, Sinner MF, Dehghan A, Lubitz SA, D’Agostino RB Sr, Lumley T, Ehret GB, Heinga R, Aspelund T, Newton-Cheh C, Larson MG, Marcante KD, Soliman EZ, Rivadeneira F, Wang TJ, Eiriksdottir G, Levy D, Psaty BM, Li M, Chamberlain AM, Hofman A, Vasan RS, et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet 2009, 41:879-881.
14. Gudbjartsson DT, Holm H, Gretarsdottr S, Thorleifsson G, Walters GB, Thorgeirsson G, Gulcher J, Mathiesen EB, Njolstad I, Nyrens A, Wieggaard T, Halld EM, Hveem K, Stoltenberg C, Kucera G, Stubbefeldt T, Carter S, Roden D, Ng MC, Baum L, So WY, Wong KS, Chan JC, Gieger C, Wichmann HE, Geschwendtner A, Dichgans M, Kuhlenbaumer G, Berger C, Ringelstein EB, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 2009, 41:676-678.
15. Ellinor PT, Lunetta KL, Glazer NL, Pfeiffer A, Alonso A, Chung MK, Sinner MF, de Bakker PI, Mueller M, Lubitz SA, Fox E, Darbar D, Smith NL, Smith JD, Schnabel R, Soliman EZ, Rice K, Van Wagoner DR, Beckmann BM, van Noord C, Wang K, Ehret GB, Rotter JI, Hazen S, Steinbeck G, Makino S, Nettis M, Milan DJ, Perez S, Esko T, et al. Common variants in KCN3 are associated with lone atrial fibrillation. Nat Genet 2010, 42:240-244.
16. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Pfeiffer A, Alonso A, Chung MK, Sinner MF, de Bakker PI, Mueller M, Lubitz SA, Fox E, Darbar D, Smith NL, Smith JD, Schnabel R, Soliman EZ, Rice K, Van Wagoner DR, Beckmann BM, van Noord C, Wang K, Ehret GB, Rotter JI, Hazen S, Steinbeck G, Makino S, Nettis M, Milan DJ, Perez S, Esko T, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012, 44:44.
19. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Heuzey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Page RL, Slotboom DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Caroggi MA, Egtinger SN, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 123:2689-307.

20. Camm AJ, Kirchhof P, Lip GY, Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, van Gelder IC, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, van Gelder IC, Fuster V, Ryden LE, Cannom DS, et al. The Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.

21. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.

22. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137:263-272.

23. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors In Atrial Fibrillation) Study. J Am Coll Cardiol 2011, 58:395-401.

24. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.

25. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Din Marco, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines D, Hassaquere M, Hindricks G, Isaia Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhaf P, Klein G, Kottkamp H, Kumogai L, Lansky AD, Mansour M, Marchlinke FI, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol 2012, 31:177-251.

26. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009, 2:349-361.

27. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. J Am Coll Cardiol 2010, 55:747-753.

28. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, Newton-Chen C, Yamamoto JF, Magnani JW, Tadmos TM, Kannel WB, Wang TJ, Ellison PT, Wolf PA, Vasan RS, Benjamin EJ. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009, 373:739-749.

29. Schnabel RB, Aspelund T, Li G, Sullivan LM, Suchy-Dicey A, Harris TB, Pencina MJ, D'Agostino RB Sr, Levy D, Kannel WB, Wang TJ, Ellison PT, Wolf PA, Vasan RS, Benjamin EJ. Impact of genetic discoveries on the classification of lone atrial fibrillation. J Am Coll Cardiol 2010, 55:705-712.

30. D'Agostino RB Jr, Levy D, Pencina MJ, Massaro JM, Crouse JR, Kannel WB, Vasan RS. The association between CYP2C9 genetic variants and warfarin dose. Circ Cardiovasc Genet 2010, 3:2285-2293.

31. Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Jaremko M, Yoo C, Desnick RJ, Halperin JL. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol 2012, 60:841-850.

32. Roberts JD, Gohb MH. Impact of genetic discoveries on the classification of lone atrial fibrillation. J Am Coll Cardiol 2010, 55:747-753.

33. Smith JG, Newton-Chen C, Almgren P, Melander O, Platonov PG, Chamberlain AM, Aggarwal SK, Folsom AR, Soliman EZ, Chambless LE. Genetic and environmental determinants of torsade de points risk. Circulation 2012, 125:1684-1694.

34. Jamieh Y, Nohe IM, Dalageorgou C, Zheng D, Johnson T, Bastaen R, Ruddy S, Talibott D, Norris K, Snieder H, George AL, Marshall V, Shako S, Kannarki PJ, Munroe PB, Camm AJ, Jeffery S, Roden DM, Behr ER. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol 2012, 60:841-850.

35. Pepe MS, Janes H, Longton G, Liavonchak W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2002, 155:894-906.

36. Brunham LR, Hayden MR. Medicine. Whole-genome sequencing: the new standard of care? Science 2012, 336:1112-1113.

37. Lubitza SM, Sinmer MF, Lunita R, Makino S, Pfeuffer A, Rahman R, Veltnam CE, Bambard J, Bis JC, Dank S, Sonni A, Schea MA, Del Monte F, Pers S, Muller M, Peters A, Greenberg SM, Furie KL, van Noord C, Boekvinken E, Stricker BH, Wittenman J, Smith JD, Chung MK, Heckbert SR, Benjamin EJ, Rosand J, Arking DE, Alonso A, Kaba S, et al. Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation 2012, 125:1958-1964.

38. Evans DM, Visscher PM, Wray NR. Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. Hum Mol Genet 2009, 18:3525-3531.

39. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P. Common polymorphic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
53. Lango Allen H, Estrada K, Lettre G, Berndt SI, Bouguen H, Wood NW, Steves CN, Smith LJ, Brown NJ, Scuteri A, H Markus S, Jih-Lang C, Simonis J, van Heel DA, Willems S, Willer CJ, Svetions A, Abellan P, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

54. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

55. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

56. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

57. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

58. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

59. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

60. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

61. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

62. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

63. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

64. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

65. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

66. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

67. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

68. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.

69. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Lifton RP, Hingorani AD, Uitterlinden AG, Chasman DI, Willer CJ, Arking DE, Moraes G, McCarthy GI, O’Connell JR, Deloukas P, Shadick NA, 100,000 Genomes Project, et al. Meta-analysis of 745,748 cases and controls identifies new loci associated with atrial fibrillation. Nat Genet 2013;45:113-120.
40 genetic polymorphisms with atrial fibrillation. Int J Cardiol 2007, 116:107-112.

87. Wirka RC, Gore S, Van Wagoner DR, Arking DE, Lubitz SA, Lunetta KL, Benjamin EJ, Alonso A, Ellinor PT, Barnard J, Chung MK, Smith JD. A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation. Circ Arrhythm Electrophysiol 2011, 4:87-93.

88. Volders PG, Zhu Q, Timmermans C, Eurlings PM, Su X, Aens VS, Li L, Jongbloed RJ, Xia M, Rodriguez LM, Chen YH. Mapping a novel locus for familial atrial fibrillation on chromosome 10p11-q21. Heart Rhythm 2007, 4:469-475.

89. Cunha SR, Hund TJ, Hashemi S, Voigt N, Li N, Wright P, Koval O, Li J, Gudmundsson H, Gurnina RJ, Karck M, Schott J-J, Probst V, Le Marec H, Anderson ME, Dobrev D, Wehrens XH, Mohler PJ. Defects in ankyrin-based membrane protein targeting pathways underlie atrial fibrillation. Circulation 2011, 124:1212-1222.

90. Schott J-J, Charpentier F, Pelto S, Foley P, Droin E, Bouhour J, Donnelly P, Vergnaud G, Bachner L, Moisan JP. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995, 57:1114-1122.

91. Brugada R, Tapsicot T, Czernuszewicz GZ, Marian AJ, Igleias A, Mont L, Brugada J, Grina J, Domingo A, Bachinski LL, Roberti R. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997, 336:905-911.

92. Waterman HS, MacRae CA, Tacke C, Wolff MR, Porco M, Frenneaux M, Atherton J, Vidallet HJ Jr, Spudich S, De Girolami U, Seidman JC, Seidman C, Muntoni F, Muehle G, Johnson W, Donnoughon B. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999, 341:7171-7174.

93. Sebillo N, Bouchier C, Bidot LD, Bonne G, Ahmed K, Charlton P, Drouin-Garraud Y, Millaire A, Desruemeaux G, Benacch A, Chamiot JC, Schwartz K, Villard E, Komajda M. Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet 2003, 40:560-567.

94. Brauch KM, Chen LY, Olson TM. Comprehensive mutation scanning of LMNA in 268 patients with lone atrial fibrillation. Am J Cardiol 2009, 103:1426-1428.

95. Pan H, Richards AA, Zhu X, Joglar JA, Yin HL, Garg V. A novel mutation in LAMIN A/C is associated with isolated early-onset atrial fibrillation and progressive atrioventricular block followed by cardiomyopathy and sudden cardiac death. Heart Rhythm 2009, 6:707-710.

96. Oberti C, Wang L, Li L, Dong J, Rao S, Du W, Wang Q. Genome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathy. Circulation 2004, 110:3753-3759.

97. Zhang X, Chen S, Yoo S, Chakraborti S, Zhang T, Ke T, Oberti C, Yong SL, Fang F, Li L, de La Fuente R, Wang L, Chen Q, Wang QK. Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death. Cell 2008, 135:1017-1027.

98. Tsai CT, Lai LF, Lin JL, Chang FT, Hwang JJ, Ritchie MD, Moore JH, Hu KL, Tseng CD, Liu CS, Tseng YZ. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004, 109:1640-1646.

99. Wang QS, Li YG, Chen XD, Yu JF, Wang J, Sun J, Lu SB, Jin L, Wang XF. Angiotensinogen polymorphisms and acquired atrial fibrillation in Chinese. J Electrocardiol 2010, 43:373-377.

100. Bedi M, McNamara D, London B, Schwartzman D. Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm 2006, 3:808-812.

101. Fatini C, Stiichi E, Genisini F, Gori AM, Marcucci R, Lenti M, Michelucci A, Genuardi M, Abbate R, Gensini GF. Lone and secondary nonvalvular atrial fibrillation: role of a genetic susceptibility. Int J Cardiol 2007, 120:59-65.

102. Watanabe H, Kaiser DW, Makino S, MacBrae CA, Ellinor PT, Waseeman BS, Kannankeril PJ, Donahue BS, Roden DM, Darbar D. ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. Heart Rhythm 2009, 6:1327-1332.

103. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublien DM, Darbar D, Herron K, Balkev JD, de Andrade M, Burmctt JC Jr, Olson TM. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 2008, 359:158-165.